Oct 6, 2025 07:01AM Cellectar gets EMA eligibility for conditional approval of cancer drug

Aug 14, 2025 07:52AM Cellectar Biosciences (CLRB) Misses Q2 EPS by 326c

Jul 1, 2025 09:25AM Cellectar Biosciences (CLRB) Announces Pricing of $6 Million Underwritten Public Offering

Jun 26, 2025 08:05AM Cellectar Biosciences (CLRB) and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 18, 2025 04:30PM Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse Stock Split

Jun 11, 2025 08:05AM Cellectar Biosciences (CLRB) Provides Update on CLOVER-2 Phase 1 Trial

Jun 5, 2025 09:00AM Cellectar Biosciences (CLRB) Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 4, 2025 01:04PM Cellectar Biosciences (CLRB) stock soars on FDA breakthrough designation

Jun 4, 2025 08:05AM Cellectar Biosciences (CLRB) Granted FDA Breakthrough Therapy Designation for Iopofosine I 131

May 13, 2025 05:57PM Cellectar Biosciences (CLRB) Tops Q1 EPS by 30c

Apr 30, 2025 08:05AM Cellectar Biosciences (CLRB) to Explore Strategic Alternatives

Jan 13, 2025 07:22AM Oppenheimer Reiterates Perform Rating on Cellectar Biosciences (CLRB)

Dec 10, 2024 05:01PM Cellectar Biosciences (CLRB) Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Dec 10, 2024 04:55PM Cellectar Biosciences (CLRB) Halted, News Pending

Nov 19, 2024 08:17AM Cellectar Biosciences (CLRB) PT Lowered to $12 at Oppenheimer

Nov 18, 2024 07:29AM Cellectar Biosciences (CLRB) Misses Q3 EPS by 7c

Nov 14, 2024 08:06AM Cellectar Biosciences (CLRB) and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Oct 11, 2024 06:10AM Oppenheimer Reiterates Outperform Rating on Cellectar Biosciences (CLRB)

Jul 24, 2024 01:58PM Cellectar Biosciences (CLRB) PT Raised to $14 at Oppenheimer

Jul 23, 2024 06:40AM Cellectar Biosciences (CLRB) Reports I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Study